Neuro-Biotech Corp Provides Updates on Unsolicited Offer

BASEL, Switzerland, Feb. 14 /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES). Dr Claude Poulin CEO is pleased to announce, that, following the Unsolicited Offer received on February 9, the Company is currently finalizing their Due Diligence and will be able to provide further details on the offering company as well as management conclusion on Tuesday February 15 at 1pm, in the form of a Press Release.

For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com

FORWARD LOOKING STATEMENTS

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

CONTACT
Neuro-Biotech Corp.
Dr. Claude Poulin
41 61 500 05 16
[email protected]
www.neuro-biotechcorp.com

SOURCE Neuro-Biotech Corp.